Trending
- Abu Dhabi radiates optimism as over 300 startups join AIM Congress 2024
- TLcom Capital Raises $154 million in Funding to Boost Its African Growth
- Africa’s $824Bn debt, resource-backed opaque loans slowing growth — AfDB
- LB Investment brings $1.2 trillion portfolio display to AIM Congress spotlight
- AmCham Summit kicks off, setting course for robust future of US-East Africa trade ties
- Why the UN is raising the red flag on the UK-Rwanda asylum treaty
- Portugal’s Galp Energia projects 10 billion barrels in Namibia’s new oil find
- Wärtsilä Energy offers tips on how Africa can navigate energy transition and grid reliability
Browsing: HIV vaccine
Kenya and Uganda are among the countries selected for the Phase 1 clinical trial of an HIV vaccine. According to the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), the first dose will be given in Lusaka, Zambia while Kenya and Uganda will receive the vaccines in a few weeks.
Dr. William Kilembe, project director of the Center for Family Health Research in Zambia (CFHRZ) and trial principal investigator, said that international partnerships are crucial in developing and evaluating HIV vaccine candidates in countries and communities where HIV vaccines will ultimately have the greatest public health impact.
“CFHRZ is proud to be part of the consortium evaluating HIVconsvX and to deliver the first dose of this experimental HIV vaccine in the HIV-CORE 006 trial,” he said.
The trial will see 88 healthy, HIV-negative adults, aged 18-55, who are considered not to be at high risk of infection, receive one …